IRLAB Therapeutics Valuation
| IRLAB-A Stock | SEK 3.35 0.16 4.56% |
At this time, the firm appears to be overvalued. IRLAB Therapeutics retains a regular Real Value of kr3.22 per share. The prevalent price of the firm is kr3.35. Our model calculates the value of IRLAB Therapeutics from analyzing the firm fundamentals such as Operating Margin of (1.68) %, return on equity of -0.28, and Return On Asset of -0.15 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that IRLAB Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of IRLAB Therapeutics is based on 3 months time horizon. Increasing IRLAB Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since IRLAB Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of IRLAB Stock. However, IRLAB Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.35 | Real 3.22 | Hype 3.35 | Naive 4.32 |
The real value of IRLAB Stock, also known as its intrinsic value, is the underlying worth of IRLAB Therapeutics Company, which is reflected in its stock price. It is based on IRLAB Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of IRLAB Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of IRLAB Therapeutics AB helps investors to forecast how IRLAB stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of IRLAB Therapeutics more accurately as focusing exclusively on IRLAB Therapeutics' fundamentals will not take into account other important factors: IRLAB Therapeutics Total Value Analysis
IRLAB Therapeutics AB is currently forecasted to have takeover price of 1.74 B with market capitalization of 525.71 M, debt of 3.57 M, and cash on hands of 401.9 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the IRLAB Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.74 B | 525.71 M | 3.57 M | 401.9 M |
IRLAB Therapeutics Investor Information
About 39.0% of the company shares are held by company insiders. The company had not issued any dividends in recent years. IRLAB Therapeutics had 5:1 split on the 28th of May 2019. Based on the key indicators related to IRLAB Therapeutics' liquidity, profitability, solvency, and operating efficiency, IRLAB Therapeutics AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in August.IRLAB Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. IRLAB Therapeutics has an asset utilization ratio of 43.98 percent. This suggests that the Company is making kr0.44 for each dollar of assets. An increasing asset utilization means that IRLAB Therapeutics AB is more efficient with each dollar of assets it utilizes for everyday operations.IRLAB Therapeutics Ownership Allocation
IRLAB Therapeutics AB has a total of 51.79 Million outstanding shares. IRLAB Therapeutics secures noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.IRLAB Therapeutics Profitability Analysis
The company reported the revenue of 207.78 M. Net Income was 51.78 M with profit before overhead, payroll, taxes, and interest of 126.05 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates IRLAB Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in IRLAB Therapeutics and how it compares across the competition.
About IRLAB Therapeutics Valuation
The stock valuation mechanism determines IRLAB Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of IRLAB Therapeutics. We calculate exposure to IRLAB Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of IRLAB Therapeutics's related companies.IRLAB Therapeutics AB operates as a drug discovery and development company that provides drugs in the field of neurological and neuropsychiatric disorders. Its pipeline candidates include IRL790, a psychomotor stabilizer for the treatment of L-dopa induced dyskinesias in Parkinsons disease and Parkinson disease psychosis IRL752, a cortical enhancer for the treatment of Parkinson disease dementia and behavioral and psychological symptoms of dementia IRL626, a fast-off D2 antagonist for use in the treatment of schizophrenia P001, a cortical enhancer program for the treatment of attention disorders and IRL448IRL555, a followup Parkinsons disease program. IRLAB Therapeutics is traded on Stockholm Stock Exchange in Sweden.
8 Steps to conduct IRLAB Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates IRLAB Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct IRLAB Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain IRLAB Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine IRLAB Therapeutics' revenue streams: Identify IRLAB Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research IRLAB Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish IRLAB Therapeutics' growth potential: Evaluate IRLAB Therapeutics' management, business model, and growth potential.
- Determine IRLAB Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate IRLAB Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for IRLAB Stock analysis
When running IRLAB Therapeutics' price analysis, check to measure IRLAB Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRLAB Therapeutics is operating at the current time. Most of IRLAB Therapeutics' value examination focuses on studying past and present price action to predict the probability of IRLAB Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRLAB Therapeutics' price. Additionally, you may evaluate how the addition of IRLAB Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |